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A stereoselective and enantiodivergent strategy for the construction of δ-lactams is described.
The strategy utilizes chiral malonic esters prepared from enantiomerically enriched mono esters
of disubstituted malonic acid. A cyclization occurs with the selective displacement of a
substituted benzyl alcohol as the leaving group. The resulting δ-lactams are then converted into
nipecotic acid analogues using straightforward transformations. The resulting nipecotic acid
analogues proved capable organocatalysts in Mannich reactions.
2009 Elsevier Ltd. All rights reserved.
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1. Introduction
δ-Lactams constitute an important class of compounds in
synthetic chemistry and biology. They are often found in
important building blocks of a variety of biologically intriguing
natural products and as key intermediates in many potent
bioactive compounds.1-4 In addition, δ-lactams are useful
precursors to piperidine analogues that are essential
pharmacophores in a number of medicinal compounds currently
on the market or in advanced clinical studies.3, 5-8 One of the
most important classes of the piperidine family is the piperidine3-carboxylic acids, otherwise known as derivatives of nipecotic
acid. These nipecotic acid analogues are important structural
motifs in several natural and synthetic bioactive molecules.1, 6-10
Hence, it is important to have a concise and efficient synthetic
strategy to prepare δ-lactams in order to construct a variety of
nipecotic acid analogues.
Recently a number of synthetic strategies have been established
to prepare δ-lactams. Some of these strategies include Nheterocyclic catalyzed intramolecular amidations,11 palladium
catalyzed intramolecular amidations,12 aza-Diels-Alder
reactions,13 intramolecular lactone-amine coupling,4 gold
catalyzed intramolecular C-C couplings of β-ketoamide to
unactivated alkenes,14 and palladium catalyzed intramolecular
hydroamidations of alkynes.15 There have also been several
methods detailing the enantioselective synthesis of δ-lactams
through ring closing metathesis reactions of enantiomerically
pure precursors,16 nitrilase catalyzed ring expansion of
aziridines,17 and the use of organophosphorus reagents as
organocatalysts.18 Unlike δ-lactams, there are few reports
detailing the asymmetric synthesis of nipecotic acid analogues;
many of these strategies rely on functional group modifications
of preformed nicotinic acids or nipecotic acid derivatives. 9, 10, 19, 20
However, the asymmetric synthesis of piperidine derivatives
utilizing a stereoselective cyclization approach is surprisingly
rare. To the best of our knowledge, Shintani et al. is the first to
report a synthesis of diastereomerically enriched nipecotic acid
analogues through a palladium catalyzed decarboxylative
cyclization.9 Therefore, there is a need for additional
straightforward methods capable of preparing enantiomerically
enriched nipecotic acid derivatives.
We have recently demonstrated that γ-lactams can be readily
prepared by a stereoselective cyclization strategy.21 These
corresponding γ-lactams were then readily converted into highly
optically enriched β-proline derivatives.21 Hence, we wanted to
employ this cyclization strategy to prepare δ-lactams in a
stereoselective manner.
2. Results and Discussion
Recently, we have reported a Pig Liver Esterase (PLE) catalyzed
asymmetric hydrolysis of the prochiral malonic ester 1.22 This
biocatalytic hydrolysis of 1 resulted in chiral malonic acid-ester 2
with high enantiomeric purity (97% ee), and good yields (71%)
as shown in the Scheme 1. The enantiomerically enriched
malonic acid-ester 2 was determined to be predominantly the (R)enantiomer by synthetic means. The acid ester 2 was then
converted into benzyl ester 3. In our previous study, we
witnessed that the para-NO2-benzyl ester readily undergoes
stereoselective cyclization upon removal of the phthalimide
protecting group. Upon treatment of 3 with hydrazine hydrate, a
cyclization took place resulting in δ-lactams 4a, and 4b as shown
in Scheme 1. The ratio of 4a:4b was 60:1 as determined by 1HNMR. Therefore, the results show a high propensity towards
cyclization along with a high selectivity to form δ-lactam 4a.

Scheme 1. Synthesis of -lactams
The strategy illustrated in Scheme 1 shows a straightforward
approach whereby the manipulation of this type of ester allows
for a high level of cyclization control. This demonstrates a simple
strategy that can be very useful in the construction of δ-lactams
and their derivatives.
We decided to further explore this cyclization strategy to obtain
4b as the major product. The ability to construct 4b as the major
product would provide access to a useful enantiodivergent
strategy to prepare δ-lactams. However, in our previous study a
Hammet study demonstrated the difficulties in acquiring 4b as
the major product simply by exploiting the electronic factors
through substituted benzyl esters. In order to address this issue,
we synthesized diester 5 from 2 to introduce steric congestion as
shown in Scheme 2.
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Scheme 2. Selective cyclization proving access to (S)-δ-lactam
From a steric congestion standpoint, the ethyl ester in 5 should be
more accessible towards nucleophilic attack by the free amine.
Upon treatment with hydrazine, 6a was obtained as the only
product and there was no indication of the formation of 6b as
indicated by 1H-NMR. 6a is a derivative of 4b with the same
absolute stereochemistry as 4b. Therefore, introduction of steric
hindrance gives rise to a highly stereoselective, and potentially
stereospecific, cyclization strategy to prepare (S)-δ-lactams. To
the best of our knowledge, this is the first time an
enantiodivergent strategy has been optimized to prepare such δlactams.
Over the last few years, Cα-methyl-nipecotic acid has served as
an important structural entity in a number of synthetic and natural
therapeutic lead compounds. For example, a group of scientists
from Merck have discovered a potent NK1 receptor antagonist,
where (R)-Cα-methyl-nipecotic acid is used as an essential
building block.7 Nisho et al. have come up with dipeptidyl
peptidase IV inhibitors consisting of (R)-Cα-Methyl-nipecotic
acid derivative serving as pharmacophore.5, 6 Despite a number of
practical applications, asymmetric synthesis of Cα-methylnipecotic acid have been rarely reported in recent years. We
wanted to demonstrate the potential impact of this cyclization
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strategy by utilizing the δ-lactams to construct enantiomerically
pure nipecotic acid analogues. Upon close inspection of 4a and
6a, it was conceived that the corresponding nipecotic acid
analogues could be prepared by the selective reduction of the δlactam to a piperidine ring. This would allow us to prepare both
enantiomers of Cα-methyl-nipecotic acid analogues and establish
it as a useful enantiodivergent strategy in the preparation of such
analogues.

Scheme 3. Synthesis of (R)-Cα-methyl-nipecotic acid analogue

Scheme 4. Synthesis of (S)-Cα-methyl-nipecotic acid analogue

To accomplish the asymmetric synthesis of (R)-Cα-methylnipecotic acid 11, we started with the enantiomerically enriched
δ-lactam 4a as shown in Scheme 3. First, δ-lactam 4a was benzyl
protected to give 7 in good yield (81%). Then the N-benzylated
lactam 7 was converted into thiolactam 8 employing Lawesson's
reagent in good yield (80%). Thiolactam 8 was selectively
reduced to the piperidine derivative 9 utilizing the Raney-Ni
desulphurization technique in good yield (78%) without further
purification. The saponification of 9 resulted in the N-benzylatednipecotic acid analogue 10 in good yield (88%) requiring no
further purification. Finally, 10 was fully deprotected by
hydrogenolysis of the benzyl group resulting in pure C α-methylnipecotic acid 11 without further purification and in good yield
(93%). Therefore, the (R)-nipecotic acid analogue was achieved
in five overall steps requiring little purification and in very good
overall yield (41%).
At this point, we wanted to use the (S)-δ-lactam 6a as the key
intermediate in the preparation of (S)-nipecotic acid analogue 17
as shown in the Scheme 4. Lactam 6a was converted into Nbenzyl protected lactam 12 in very good yield (80%). In the next
step we discovered that the tert-butyl ester was not tolerated
under the conditions utilized to prepare the thiolactam. To
circumvent this problem, the tert-butyl ester was cleaved and
reprotected as methyl ester 13 in one pot (89%). Lactam 13 was
then converted into thiolactam 14 utilizing Lawesson's reagent in
good yield (78%). Thiolactam 14 was subject to Raney-Ni
desulphurization resulting in (S)-piperidine-3-carboxylate 15 in
good yield (80%). Saponification of 15 resulted in (S)-Nbenzylated nipecotic acid derivative 16 in 75% yield. Compound
16 was subjected to hydrogenation to achieve (S)-nipecotic acid
analogue 17 in very good yield (92%). The specific rotation
confirms 17 as the enantiomer of 11. This success provides
access to the (S)-nipecotic acid analogue 17 with a limited
number of steps and a respectable overall yield of 31%.

With the nipecotic acids in hand, we wanted to explore the
organocatalytic efficiency of (R)-Cα-methyl-nipecotic acid 11 in
Mannich type reactions. To the best of our knowledge, Zhang et
al. are the first to test (R)-nipecotic acid as a catalyst in Mannich
reactions.23 They observed (R)-nipecotic acid to produce the
Mannich product with moderate anti-selectivity (anti/syn = 78 :
22) and enantioselectivity (anti = 36% ee, syn =12% ee).23 In this
context, we wanted to envisage if the enhanced rigidity employed
by an additional methyl group in 11 would play a role in the
selectivity of the resulting Mannich product. We performed the
same Mannich reaction tested by Zhang et al. as shown in
Scheme 5 employing 30 mol % of 11 as an organocatalyst.23 The
reaction was complete within 12 h and the Mannich product was
obtained upon purification in reasonable yield (78%). Chiral
HPLC (Figure 1) and 1H-NMR established the product as
moderately anti-selective (anti/syn = 72.5:27.5), and with slightly
diminished ee of anti-enantiomers (anti = 26% ee) compared to
literature.

Scheme 5. Cα-Methyl-nipecotic acid catalyzed Mannich reaction
It is evident from the experimental data that Cα-methyl nipecotic
acid 11 provides the Mannich product with approximately the
same anti/syn-selectivity as nipecotic acid, but with slightly
diminished enantiomeric excess for the anti-Mannich product.
Based on the obtained result, we propose that C α-methylnipecotic acid 11 prefers the (S)-cis-enamine and has a slight
preference to react with the imine at the si-face as shown in
Figure 2.
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4. Experimental
Synthesis
of
diethyl-2-[3-(1,3-dioxoisoindolin-2-yl)-2methylmalonate 1: Diester 1 was obtained from the reaction
between 10 g of diethyl-2-methylmalonate (57.4 mmol), 15.40 g
(57.4 mmol) of N-(bromopropyl)-phthalimide and 2.74 g (68.9
mmol) of NaH following a literature procedure. An amount of
12.8 g (35.4 mmol, 62%) pure 1 was obtained as colorless liquid
upon purification by column chromatography (30 : 70
EtOAc/hexanes). Characterization data of 1 matched literature
values.22

Figure 1. Chiral HPLC (Daicel Chairalcel AS-H, hexanes /iPrOH = 99:1, 1.0 mL/min, λ = 254 nm) of (R)-Cαmethylnipecotic acid 11 catalyzed Mannich product.

Figure 2. Proposed transition state of Cα-methyl-nipecotic acid
catalyzed Mannich reaction
3. Conclusions
We have optimized a highly enantioselective and
enantiodivergent cyclization strategy for the preparation of δlactams starting with the enantiomerically enriched common
intermediate 2. This is the first reported strategy in which δlactams are prepared in a highly stereoselective manner simply
by regulating steric and electronic factors. We believe that this
straightforward approach will provide access to a wide variety of
enantiomerically enriched δ-lactams. We have demonstrated that
both the (R)- and (S)-δ-lactams can be readily converted into their
respective nipecotic acid analogues. This success provides access
to a concise and enantiodivergent approach to potentially achieve
a number of highly demanding enantiomerically enriched
nipecotic acid analogues. We have explored C α-methyl-nipecotic
acid as a catalyst in the Mannich reaction. Our initial results
show that Cα-methyl-nipecotic acid provides a similar
diastereomeric excess as nipecotic acid but with diminished %ee
(36% ee to 26% ee) for the anti-diastereomers. We suspect that
the increased rigidity of the piperidine ring introduced by an
additional methyl group is responsible for the reduced %ee.

Synthesis
of
(R)-5-(1,3-dioxoisoindolin-2-yl)-2(ethoxycarbonyl)-2-methylpentanoic acid 2: Compound 2 was
prepared from 10 g of 1 (28 mmol) employing pig liver esterase
(PLE) catalyzed desymmetrization following a literature
procedure.22 The resulting half-ester was purified by flash
chromatography (40:60 EtOAc/hexanes) to give 6.60 g of the
product as a colorless liquid (20 mmol, 68%). The % ee was
determined to be 97% by chiral HPLC (Diacel Chiralpak OJ-H,
4% iPrOH/hexanes, flow rate = 1 mL/min, λ = 305 nm) Rt (S) =
54.9 min (Area = 130.13), Rt(R) = 58.8 min (Area = 7770.41). Rf
= 0.22 (40% EtOAc/hexanes). IR (cm-1) = 2983, 2937, 1773,
1747, 1697. []D24 = + 5.8 (c 2, MeOH). 1H-NMR (CDCl3, 400
MHz): δ 7.85 (m, 2H), 7.73 (m, 2H), 4.21 (q, 2H, J = 7Hz), 3.71
(t, 2H, J = 7Hz), 1.93 (m, 2H), 1.71 (m, 2H), 1.45 (s, 3H), 1.26 (t,
3H, J = 7Hz). 13C-NMR (CDCl3, 100 MHz): δ 176.0, 172.0,
168.0, 134.0, 132.0, 123.0, 62.0, 53.0, 38.0, 33.0, 24.0, 20.0,
14.0. HRMS [C17H19NO6Na+] calcd = 356.3256, found =
356.3253.
Synthesis of (S)-1-ethyl 3-(4-nitrobenzyl) 2-[3-(1,3dioxoisoindolin-2-yl)propyl]-2-methylmalonate 3: A 250 mL
round-bottom ﬂask was charged with 6.41 g of 2 (19 mmol), 2.62
g of K2CO3 (19 mmol), 75 mL of anhydrous DMF, and a stir bar.
A solution of the 4-nitrobenzyl bromide (17.1 mmol) in 20 mL of
anhydrous DMF was slowly added over 15 min. The reaction
was allowed to stir approximately 12 h under a nitrogen
atmosphere. The reaction mixture was then diluted with 100 mL
of water, and the resulting mixture was washed with Et2O (3 ×
150 mL). The combined ether layer was washed with water (8 ×
150 mL) and brine (2 × 100 mL), dried over MgSO4, filtered, and
the solvent was removed under reduced pressure. The product
was isolated by ﬂash chromatography (30% EtOAc/hexanes),
giving 8.10 g (17.4 mmol, 87%) pure 3 as a white solid. Rf = 0.1
(30% EtOAc/hexanes). []D23 = -33.0 (c 1, CH2Cl2). mp = 66
O
C. IR (cm-1) = 2982, 1775, 1710. 1H-NMR (CDCl3, 400 MHz):
δ 8.19 (d, 2H, J = 8.32 Hz), 7.81 (m, 2H), 7.72 (m, 2H), 7.46 (d,
2H, J = 8.32 Hz), 5.22 (m, 2H), 4.15 (q, 2H, J = 7 Hz), 3.68 (t,
2H, J = 7 Hz), 1.95 (m, 2H), 1.65 (m, 2H), 1.44 (s, 3H), 1.18 (t,
3H, J = 7 Hz). 13C-NMR (CDCl3, 100 MHz): δ 171.5, 168.2,
148.7, 134.0, 132.0, 128.2, 124.0, 123.3, 65.2, 61.4, 58.5, 53.0,
37.8, 33.0, 24.0, 20.0, 18.2, 13.6. HRMS [C 24H24N2O8Na+] calcd
= 491.1425, found = 491.1422.
Synthesis
of
(R)-ethyl
3-methyl-2-oxopiperidine-3carboxylate 4a: A volume of 1.8 mL (20 mmol) 35% hydrazine
in water was added to a solution of 5.10 g (11 mmol) of 3 in 50
mL of MeOH. The mixture was heated at reﬂux overnight. A
white precipitate was observed within 1 h of reﬂux. The reaction
mixture was allowed to cool to room temperature, and the
resulting mixture was ﬁltered through a polypropylene 0.2 mm
pore size syringe filter. An amount of 1.36g (9.9 mmol) of K2CO3
was added to the filtrate. The solution was allowed to reflux for 6
h, after which the solvent was evaporated under reduced pressure.
The resulting residue was taken up in CH2Cl2 and washed with
water. The organic layer was dried over MgSO4, evaporated
under reduced pressure, and puriﬁed by column chromatography
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using 60% Hexanes/EtOAc giving 1.5g (8.3 mmol, 75%) of 4 as
a white solid. Rf = 0.35 (30% EtOAc/hexanes). []D24 = + 29.2
(c 1, CH2Cl2). mp = 65 OC. IR (cm-1) = 3219.6, 2940.4, 2871.9,
1726.5, 1655.5. 1H-NMR (CDCl3, 400 MHz): δ 6.25 (bs, 1H), 4.2
(m, 2H), 3.36 (m, 2H), 2.26 (m, 1H), 1.84 (m, 2H), 1.73 (m, 1H),
1.50 (s, 3H), 1.27 (t, 3H, J = 7 Hz). 13C-NMR (CDCl3, 100
MHz): δ 173.6, 172.0, 61.2, 50.3, 42.3, 33.0, 22.4, 90.4, 14.0.
HRMS [C9H15NO3Na+] calcd = 208.0944, found = 208.0944.
Synthesis of (S)-1-tert-butyl 3-ethyl 2-methyl-2-(3-(1,3dioxoisoindolin-2-yl)propyl)malonate 5: A volume of 600 µL
conc. H2SO4 was added to a solution of 2 g of 2 (6 mmol) in 30
mL of CH2Cl2 in a 100 mL sealed tube. The solution was cooled
to -7 oC. A volume of 6 mL of condensed isobutylene was added
to the solution. The tube was sealed tightly and allowed to stir
overnight at rt. The tube was uncapped and allowed to stir for 2h
at ambient pressure to allow excess isobutylene to evaporate. The
solution was diluted with 30 mL of CH2Cl2 and gently washed
three times with 1M NaOH (50 mL). The CH2Cl2 layer was dried
over MgSO4, evaporated under reduced pressure, and
chromatographed (40% EtOAc/hexanes), giving 2 g (5.1 mmol,
87%) of 5 as a white solid. Rf = 0.53 (40% EtOAc/hexanes).
[]D23 = -5.2 (c 1, MeOH). MP = 77 OC. IR (cm-1): 2976.2,
2936.4, 1771.3, 1712.5. 1H-NMR (CDCl3, 400 MHz): 7.84 (m,
2H), 7.71 (m, 2H), 4.18 (m, 2H), 3.74 (m, 2H), 1.91 (m, 2H),
1.61 (m, 2H), 1.48 (s, 9H), 1.39 (s, 3H), 1.28 (t, 3H, J = 7 Hz).
13
C-NMR (CDCl3, 100MHz) 172.3, 171.03, 168.3, 134.0, 132.1,
123.2, 81.5, 61.1, 54.0, 38.1, 34.7, 28.0, 25.3, 20.0, 14.0. HRMS
[C21H27NO6Na+]: calcd = 412.1730, found = 412.1730.
Synthesis of (S)-tert-butyl 3-methyl-2-oxopiperidine-3carboxylate 6a: A volume of 398 µL (4.4 mmol) 35% hydrazine
in water was added to a solution of 1.50 g (4 mmol) of 5 in 25
mL of MeOH. The mixture was heated at reflux overnight. A
white precipitate was observed within an hour of reflux. The
reaction mixture was allowed to cool to RT and the solution was
filtered. An amount of 0.55 g of K2CO3 (4 mmol) was added to
the filtrate, and the solution was allowed to reflux for another 6 h.
The solvent was evaporated under reduced pressure and the
residue taken up in CH2Cl2. The resulting mixture was washed
with water and the organic layer was dried over MgSO4,
evaporated under reduced pressure, and chromatographed using
30% hexanes/EtOAc giving 0.62 g (3 mmol, 75%) of 6a as a
white solid. Rf (6a) = 0.27 (30% hexanes/EtOAc). mp = 130 OC.
IR (cm-1): 3218.5, 2975.6, 2938.5, 2870.8, 1726.7,1660.3. []D23
= -16.2 (c 1, CH2Cl2). 1H-NMR (CDCl3, 400 MHz): 6.28 (bs,
1H), 3.61 (m, 2H), 2.2 (m, 1H), 1.8 (m, 2H), 1.61 (m, 1H), 1.42
(s, 12H). 13C-NMR (CDCl3, 100 MHz): 174.2, 173.9, 83.0, 51.0,
43.0, 34.0, 28.0, 20.0, 14.0. HRMS [C 11H19NO3Na+]: calcd =
236.1257, found = 236.1258.
Synthesis of (R)-ethyl 1-benzyl-3-methyl-2-oxopiperidine-3carboxylate 7: A solution of 0.30 g (1.6 mmol) of 4a in 10 mL
of anhydrous THF was added slowly to a suspension of 0.046 g
NaH (1.92 mmol) in 10 mL of THF at 0 °C under an N2
atmosphere. The reaction mixture was allowed to stir for 5 min.
A volume of 210 µL (1.76 mmol) of BnBr was added dropwise
to the reaction mixture at 0 °C. The reaction mixture was allowed
to stir for 10 min at 0 °C and then allowed to warm to rt. The
reaction was continued for 1h at rt. A volume of 6 mL of dry
DMF was added to the reaction mixture, which continued to stir
for 2 h. The reaction mixture was poured into 15 mL of H2O. The
water layer was extracted with Et2O (3 × 25 mL). The combined
ether layer was washed with water (3 × 10 mL), dried over
MgSO4,
evaporated
under
reduced
pressure,
and
chromatographed (gradient, 15−20% EtOAc/hexanes) giving
0.36 g (1.3 mmol, 81%) of pure 7 as a colorless oil. Rf = 0.3
(20% EtOAc/hexanes). []D24 = + 62.6 (c 2, CH2Cl2). IR (cm-1)
= 3219.6, 2940.4, 2871.9, 1726.5, 1655.5. 1H-NMR (CDCl3, 400

MHz): 7.29 (m, 5H), 5.0 (d, 1H, J = 14.24 Hz), 4.2 (m, 3H),
3.24 (m, 2H), 2.23 (m, 1H), 1.79 (m, 3H), 1.54 (s, 3H), 1.29 (t,
3H, J = 7 Hz). 13C-NMR (CDCl3, 100 MHz): δ 173.6, 169.3,
137.2, 128.5, 127.8, 127.3, 61.4, 50.7, 50.4, 47.3, 33.4, 22.7,
19.4, 14.2. HRMS [C16H21NO3Na+] calcd = 298.1413, found =
298.1411.
Synthesis of (S)-ethyl 1-benzyl-3-methyl-2-thioxopiperidine3-carboxylate 8: A 1.70 g (4.2 mmol) portion of Lawesson’s
reagent was added to a solution of 1.30 g (4.7 mmol) of 7 in 20
mL of anhydrous toluene under an N2 atmosphere. The reaction
mixture was heated to 95 °C and stirred for over 12 h. The
reaction completion was verified by TLC (20% EtOAc/hexanes).
The toluene layer was evaporated under reduced pressure, and
the residue was chromatographed (20% EtOAc/hexanes) giving
0.97 g (3.3 mmol, 80%) of 8 as a colorless oil. The conversion of
lactam 7 to the corresponding thiolactam 8 was conﬁrmed by
comparing the 13C NMR chemical shift of the lactam 7 carbonyl
carbon (173.6 ppm) to thiolactam 8 carbonyl carbon (202.5 ppm).
Rf = 0.3 (20% EtOAc/hexanes). []D22 = +75.2 (c 1, CH2Cl2). IR
(cm-1) = 2936.7, 1731.3, 1506.9. 1H-NMR (CDCl3, 400 MHz): δ
7.31 (m, 5H), 5.69 (d, 1H, J = 14.37 Hz), 5.04 (d, 1H, J = 14.37
Hz), 4.23 (m, 2H), 3.43 (m, 2H), 2.28 (m, 1H), 2.01 (m, 1H),
1.83 (m, 2H), 1.75 (s, 3H), 1.30 (t, 3H, J = 7 Hz). 13C-NMR
(CDCl3, 100 MHz): δ 202.5, 173.6, 135.0, 129.0, 127.7, 127.5,
61.5, 57.7, 55.5, 50.4, 32.1, 27.8, 19.4, 14.0. HRMS
[C16H21NO2SNa+] calcd = 314.1185, found = 314.1184.
Synthesis of (R)-ethyl 1-benzyl-3-methylpiperidine-3carboxylate 9: A 0.80 g portion of 8 (2.7 mmol) was dissolved in
20 mL of 4:1 THF/EtOH. A 0.16 g portion of Raney-Ni slurry in
water (20% by weight) was added to the solution. The solution
was stirred vigorously under a H2 atmosphere for 6 h, at which
point the reaction was found to be half-complete by TLC (10%
hexanes/CH2Cl2). The mixture was continued to stir under an H2
atmosphere another 6 h. The reaction was found to be completed
via TLC to give 0.54 g (2 mmol, 78%) of 9 as a colorless liquid.
Rf = 0.35 (20% hexanes/CH2Cl2).
[]D21
= + 11.8 (c 1,
-1
CH2Cl2). IR (cm ) = 2939.4, 2795.4, 1725.9. 1H- NMR (CDCl3,
400 MHz): 7.29 (m, 5H), 4.43 (m, 2H), 3.52 (d, 1H, J = 13.54
Hz), 3.40 (d, 1H, J = 13.59 Hz), 2.97 (bm, 1H), 2.58 (bm, 1H),
2.02 (m, 3H), 1.73 (m, 1H), 1.59 (m, 1H), 1.21 (t, 3H, J = 7 Hz),
1.16 (bs, 1H), 1.13 (s, 3H). 13C-NMR (CDCl3, 100 MHz): 176.5,
138.2, 128.8, 127.0, 63.1, 62.0, 60.2, 54.0, 43.1, 33.2, 24.0, 23.0,
14.0. HRMS [C16H23NO2Na+] calcd = 284.1621, found =
284.1621.
Synthesis of (R)-1-benzyl-3-methylpiperidine-3-carboxylic
acid 10: A 0.125 g portion of crushed LiOH powder (5.2 mmol)
was added to a solution of 0.46 g (1.7 mmol) of 9 in 20 mL of 3:2
H2O/EtOH. The reaction was stirred at rt overnight. The reaction
was determined to be complete by TLC (5% MeOH/CH2Cl2).
The mixture was acidiﬁed to pH 3 (10% HCl), and the water
layer was evaporated under reduced pressure giving a colorless
gummy residue. The gummy residue was triturated with 10%
MeOH/CH2Cl2 (20 mL x 20), and the MeOH fractions were dried
over MgSO4. The solvent was removed under reduced pressure
giving 0.36 g (1.56 mmol, 88%) of 10 as a white solid as verified
by TLC and staining with bromocresol green. R f = 0.15 (5%
MeOH/CH2Cl2). []D22 = + 19.0 (c 1, MeOH). IR (cm-1) =
3367.5, 2961.4, 1706.1. 1H- NMR (CD3OD, 400 MHz): δ 7.52
(m, 5H), 4.50 (d, 1H, J = 13.61Hz), 4.17 (d, 1H, J = 13.59 Hz),
3.60 (d, 1H, J = 13.3 Hz), 3.40 (d, 1H, J = 13.3 Hz), 3.10 (m,
1H), 2.80 (d, 1H, J = 13.40 Hz), 2.20 (d, 1H, J = 13.40 Hz), 1.98
(m, 1H), 1.80 (m, 1H), 1.54 (m, 1H), 1.2 (s, 3H). 13C-NMR
(CD3OD, 100 MHz): δ 178.1, 132.0, 131.2, 130.4, 130.3, 62.1,
57.7, 55.0, 43.4, 33.0, 24.1, 22.1. HRMS [C14H19NO2Na+] calcd
= 256.1308, found = 256.1309.
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Synthesis of (R)-3-methylpiperidine-3-carboxylic acid (11):
A 0.30 g (1.3 mmol) portion of 10 was dissolved in 15 mL of
MeOH and added to 0.06 g Pd/C (20% by weight). The solution
was allowed to stir overnight under a H2 atmosphere at rt. The
resulting mixture was ﬁltered through Celite, and the ﬁltrate was
evaporated under reduced pressure giving 0.185 g (1.29 mmol,
93%) of 11 as a white solid. mp = 90 OC, []D24 = +1.2 (c 1,
MeOH), Rf = 0.08 (5% MeOH/CH2Cl2). IR (cm-1) = 3374.7,
2959.4, 1706.1. 1H-NMR (CD3OD, 400 MHz): δ 3.53 (d, 1H, J =
12.56 Hz), 3.28 (m, 1H), 2.97 (m, 1H), 2.83 (d, 1H, J = 12.56
Hz), 2.19 (d, 1H, J = 12.56 Hz), 1.88 (m, 1H), 1.69 (m, 1H), 1.58
(m, 1H), 1.27 (s, 3H). 13C-NMR (CD3OD, 100 MHz): δ 178.5,
50.10, 44.3, 41.4, 33.5, 23.5, 21.0. ESI-MS [C7H13NO2H+] calcd
= 143.1, found = 144.1. We could not perform HRMS analysis
due to the molecular weight being lower than the detection limit
of the instrument.
Synthesis of (S)-tert-butyl 1-benzyl-3-methyl-2-oxopiperidine3-carboxylate 12: A solution of 1.0 g (4.7 mmol) of 6a in 20 mL
of anhydrous THF was added slowly to a suspension of 0.14 g
NaH (5.6 mmol) in 10 mL of THF at 0 °C under an N2
atmosphere. The reaction mixture was allowed to stir for 5 min.
A volume of 0.63 µL (5.2 mmol) of BnBr was added dropwise to
the reaction mixture at 0 °C. The reaction mixture was allowed to
stir for 10 min at 0 °C and then allowed to warm to rt. The
reaction was continued for 1 h at rt. A volume of 20 mL of dry
DMF was added to the reaction mixture, which continued to stir
for 2 h. The reaction mixture was poured into 15 mL of H2O. The
water layer was extracted with Et2O (3 × 25 mL). The combined
ether layer was washed with water (3 × 10 mL), dried over
MgSO4,
evaporated
under
reduced
pressure,
and
chromatographed (gradient, 15−20% EtOAc/hexanes) giving
1.20 g (3.8 mmol, 80%) of pure 12 as a white solid. Rf = 0.32
(20% EtOAc/hexanes). []D24 = - 64.2 (c 1, CHCl3). mp = 108
O
C IR (cm-1) = 2977.8, 2933.4, 1727.5, 1625.9. 1H-NMR (CDCl3,
400 MHz): 7.28 (m, 5H), 5.04 (d, 1H, J = 14.54 Hz), 4.16 (d, 1H,
J = 14.54 Hz), 3.22 (m, 2H), 2.21 (m, 1H), 1.76 (m, 3H), 1.47
(m, 12H). 13C-NMR (CDCl3, 100 MHz): δ 173.0, 170.2, 137.4,
128.5, 128.0, 127.3, 81.4, 51.3, 50.5, 47.4, 33.5, 28.0, 22.3, 20.0.
HRMS [C18H25NO3Na+] calcd = 326.1726, found = 326.1728.
Synthesis of (S)-methyl 1-benzyl-3-methyl-2-oxopiperidine-3carboxylate 13: A volume of 3 mL TFA was added to a solution
of 1 g 12 (3.2 mmol) in 25 mL CH2Cl2. The reaction was
continued to stir over 2 h at ambient temperature. At which point
the reaction was found to be completed as evident by TLC and
ESI-MS. The methylene chloride layer was evaporated and the
residue was dissolved in 20 mL of DMF. An amount of 0.50 g
(3.6 mmol) K2CO3 was added to the solution, followed by, an
amount of 0.91 g (6.4 mmol) of CH3I. The reaction was
continued to stir under N2 atmosphere over 3h at which point the
reaction was found to be completed by TLC. The reaction
mixture was poured into 50 mL of H2O. The water layer was
extracted with Et2O (3 x 50 mL). The combined ether layer was
extracted with water, washed with brine, dried over MgSO4, and
evaporated out to dryness giving 0.74 g (2.85 mmol, 89%) of
pure 13 as a colorless oil. []D22 = – 40.0 (c 0.7, CHCl3). Rf =
0.29 (20% EtOAc/hexanes). IR (cm-1) = 2948.6, 1730.8, 1634.6.
1
H-NMR (CDCl3, 400 MHz) 7.30 (m, 5H), 4.81 (d, 1H, J = 14.27
Hz), 4.41 (d, 1H, J = 14.27 Hz), 3.74 (s, 3H), 3.24 (m, 2H), 2.25
(m, 1H), 1.77 (m, 3H), 1.54 (s, 3H). 13C-NMR (CDCl3, 100
MHz) δ 174.4, 169.8, 137.2, 128.6, 127.8, 127.3, 52.3, 50.7,
50.5, 47.3, 33.4, 22.9, 19.7. HRMS [C15H19NO3Na+] calcd =
284.1257, found = 284.1258.
Synthesis
of
(R)-methyl
1-benzyl-3-methyl-2thioxopiperidine-3-carboxylate 14: A 1.03 g (2.5 mmol)
portion of Lawesson’s reagent was added to a solution of 0.70 g
(2.7 mmol) of 13 in 20 mL of anhydrous toluene under a N2

atmosphere. The reaction mixture was heated to 95 °C and stirred
over 12 h. The reaction completion was verified by TLC (20%
EtOAc/hexanes). The toluene layer was evaporated under
reduced pressure, and the residue was chromatographed (20%
EtOAc/hexanes) giving 0.58 g (2.1 mmol, 78%) of 14 as
colorless oil. The conversion of lactam 13 to the corresponding
thiolactam 14 was conﬁrmed by comparing the 13C-NMR
chemical shift of the lactam 13 carbonyl carbon (173.6 ppm) to
the thiolactam 14 carbonyl carbon (202.3 ppm). Rf = 0.33 (20%
EtOAc/hexanes).
[]D22
= - 15.7 (c 1, CHCl3). 1H-NMR
(CDCl3, 400 MHz): δ 7.33 (m, 5H), 5.35 (m, 2H), 3.76 (s, 3H),
3.42 (m, 2H), 2.30 (m, 1H), 1.92 (m, 3H), 1.75 (s, 3H). 13CNMR (CDCl3, 100 MHz): 202.3, 174.1, 135.3, 128.8, 127.7,
127.5, 58.0, 56.1, 52.7, 50.4, 32.4, 27.7, 19.3. HRMS
[C15H19NO2SNa+] calcd = 300.1028, found = 300.1029.
Synthesis of (S)-methyl 1-benzyl-3-methylpiperidine-3carboxylate 15: A 0.40 g portion of 14 (1.4 mmol) was dissolved
in 20 mL of 4:1 THF/EtOH. A 0.08 g portion of Raney-Ni slurry
in water (20% by weight) was added to the solution. The solution
was stirred vigorously under a H2 atmosphere for 6 h at which
point the reaction was found to be half-complete by TLC (10%
hexanes/CH2Cl2). The mixture was continued to stir under H2
atmosphere for another 6 h. The reaction was found to be
completed via TLC to give 0.27 g (1.12 mmol, 80%) of 15 as a
colorless liquid. Rf = 0.33 (20% hexanes/CH2Cl2). []D23 = 5.0 (c 0.8, CHCl3). IR (cm-1) = 2954.8, 2794.6, 1729.6. 1H- NMR
(CDCl3, 400 MHz): 7.26 (m, 5H), 3.66 (s, 3H), 3.53 (d, 1H, J =
13.01 Hz), 3.40 (d, 1H, J = 13.01 Hz), 2.94 (m, 1H), 2.59 (m,
1H), 2.09 (m, 2H), 1.92 (m, 1H), 1.73 (m, 1H), 1.60 (m, 1H),
1.14 (m, 4H). 13C-NMR (CDCl3, 100 MHz): 176.9, 138.6, 128.7,
127.9, 126.8, 62.9, 61.7, 54.0, 51.4, 43.3, 33.3, 23.9, 22.9. HRMS
[C15H21NO2Na+] calcd = 270.1464, found = 270.1466.
Synthesis of (S)-1-benzyl-3-methylpiperidine-3-carboxylic
acid 16: A 0.89 g portion of crushed KOH powder (16 mmol)
was added to a solution of 0.20 g (0.8 mmol) of 15 in 20 mL of
EtOH. The reaction was allowed to reflux overnight. The
reaction was determined to be complete by TLC (5%
MeOH/CH2Cl2). The mixture was acidiﬁed to pH 3 (10% HCl),
and the water layer was evaporated under reduced pressure
giving a colorless gummy residue. The gummy residue was
triturated with 10% MeOH/CH2Cl2 (20 mL x 20), and the MeOH
fractions were dried over MgSO4. The solvent was removed
under reduced pressure giving 0.14 g (0.6 mmol, 75%) of 16 as a
white wax. []D22 = - 9.5 (c 1, MeOH). Characterization data
of 16 matched that of 10.
Synthesis of (S)-3-methylpiperidine-3-carboxylic acid 17: A
0.30 g (1.3 mmol) portion of 10 was dissolved in 15 mL of
MeOH and added to 0.06 g Pd/C (20% by weight). The solution
was allowed to stir overnight under a H2 atmosphere at rt. The
resulting mixture was ﬁltered through Celite, and the ﬁltrate was
evaporated under reduced pressure giving 0.185 g (1.29 mmol,
93%) of 17 as an oil. []D24
= -1.5 (c 1, MeOH).
Characterization data of 17 matched that of 11.
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